Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Overview of attention for article published in SpringerPlus, April 2013

Altmetric Badge

Mentioned by

facebook: 1 Facebook page

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 12 Mendeley

Summary Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Open Access, 25 Apr 2013

Monoclonal antibodies bevacizumab and cetuximab both improve overall survival (OS), progression free survival (PFS) and overall…